Mylotarg

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Acute Promyelocytic LeukemiaLeukemia, Myeloid, Acute

15 competitors in Acute Promyelocytic Leukemia

#DrugCompanyPhaseTrials

1

Idamycin

Pfizer

Approved

92

Cytosar

Teva

Approved

83

Trisenox

CCephalon

Approved

204

Jakafi

Incyte

Approved

15

Istodax

Teva

Approved

—6

Scemblix

Novartis

Approved

—7

Novantrone

EMD Serono

Approved

38

Cerubidine

HHikma Pharmaceuticals LLC

Approved

19

Novantrone

Pfizer

Phase 3

310

Venclexta

AbbVie

Phase 3

2Show 5 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Leukemia2 trials

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Completed·Pfizer·Phase 4·NCT00304447·30 enrolled

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Completed·Pfizer·Phase 2·NCT00044733·38 enrolled

Acute Myeloid Leukemia1 trial

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Completed·GGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias·Phase 2·NCT01698879·46 enrolled

Transplantation1 trial

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Relapse1 trial

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Completed·AAcute Leukemia French Association·Phase 1/2·NCT02182596·20 enrolled

Acute Promyelocytic Leukemia1 trial

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Recruiting·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 2·NCT04793919·89 enrolled

5 more indications

MDS1 trial

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00195000·43 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Terminated·VVor Biopharma·Phase 1/2·NCT04849910·67 enrolled

CAR1 trial

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Completed·Pfizer··NCT00161668·500 enrolled

Myelodysplastic Syndrome1 trial

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2/3·NCT00038805·3 enrolled

Leukemia, Myeloid, Acute1 trial

Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study

Active, not recruiting·SShaare Zedek Medical Center·Phase 2·NCT05599360·20 enrolled

Details

Drug Info

Related News